Condition: Multiple Myeloma · Sponsor: European Myeloma Network B.V.
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
This description comes directly from the study's public registry record.
Christine Witty · +31 10 268 70 65 · Christine.Witty@emn.org
Sabrin Tahri · +31 10 268 70 65 · Sabrin.Tahri@emn.org
Always discuss trial participation with your own doctor first.
| Banner University Medical Center Tucson, University of Arizona | Phoenix, Arizona, United States | Recruiting |
| UCLA Medical Center | Los Angeles, California, United States | Not Yet Recruiting |
| University of California-Davis Cancer Center | Sacramento, California, United States | Recruiting |
| University of California, San Diego (UCSD) Medical Center | San Diego, California, United States | Recruiting |
| University of Colorado Hospital | Aurora, Colorado, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Yale New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| Christiana Care | Newark, Delaware, United States | Recruiting |
| Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| AdventHealth/Blood & Marrow Transplant Center, Florida Hospital Medical Group | Orlando, Florida, United States | Recruiting |
| Moffitt at Memorial Healthcare System | Tampa, Florida, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
+ 200 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05243797